²»Á¼Ñо¿Ëù

²»Á¼Ñо¿Ëù, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability R...

²»Á¼Ñо¿Ëù launches Early Access for ioHepatocytes for disease and drug studies with consistent, functional human iPSC-derived hepato...

Focus on Tools for the Research, Drug Discovery and Cell Therapy Markets.

Modulate gene activity in human iPSC-derived cells with a set of CRISPR-ready tools for gene knockout, activation, and interferenc...

Adding New Visualisation Functionality to Human iPSC-derived Cell Types

Explore insights from ²»Á¼Ñо¿Ëù Senior Scientist Andreas as he shares his experiences judging the iGEM competition.

The European Patent Office (EPO) upholds ²»Á¼Ñо¿Ëù's patent for its dual genomic safe harbour technology, opti-oxâ„¢, securing the bro...

²»Á¼Ñо¿Ëù has been named one of the UK's most successful tech companies in the prestigious Future Fifty report. Discover how our syn...